Singleton Matthew J.'s most recent trade in Viking Therapeutics Inc was a trade of 18,800 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on Jan. 2, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Viking Therapeutics Inc | J. Matthew Singleton | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 18,800 | 18,800 | - | - | Stock Option (Right to Buy) | |
| Viking Therapeutics Inc | J. Matthew Singleton | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.48 per share. | 25 Oct 2024 | 16,000 | 25,500 (0%) | 0% | 4.5 | 71,680 | Common Stock, par value $0.00001 per share |
| Viking Therapeutics Inc | J. Matthew Singleton | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Oct 2024 | 16,000 | 0 | - | - | Stock Option (Right to Buy) | |
| Viking Therapeutics Inc | J. Matthew Singleton | Director | Sale of securities on an exchange or to another person at price $ 79.50 per share. | 25 Oct 2024 | 16,000 | 9,500 (0%) | 0% | 79.5 | 1,272,000 | Common Stock, par value $0.00001 per share |
| Viking Therapeutics Inc | J. Matthew Singleton | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Sep 2024 | 10,300 | 0 | - | - | Stock Option (Right to Buy) | |
| Viking Therapeutics Inc | J. Matthew Singleton | Director | Sale of securities on an exchange or to another person at price $ 69.50 per share. | 20 Sep 2024 | 10,300 | 9,500 (0%) | 0% | 69.5 | 715,850 | Common Stock, par value $0.00001 per share |
| Viking Therapeutics Inc | J. Matthew Singleton | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.19 per share. | 20 Sep 2024 | 10,300 | 19,800 (0%) | 0% | 1.2 | 12,257 | Common Stock, par value $0.00001 per share |
| Viking Therapeutics Inc | J. Matthew Singleton | Director | Sale of securities on an exchange or to another person at price $ 69.72 per share. | 21 Aug 2024 | 5,700 | 9,500 (0%) | 0% | 69.7 | 397,430 | Common Stock, par value $0.00001 per share |
| Viking Therapeutics Inc | J. Matthew Singleton | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.19 per share. | 21 Aug 2024 | 5,700 | 15,200 (0%) | 0% | 1.2 | 6,783 | Common Stock, par value $0.00001 per share |
| Viking Therapeutics Inc | J. Matthew Singleton | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Aug 2024 | 5,700 | 10,300 | - | - | Stock Option (Right to Buy) | |
| Viking Therapeutics Inc | J. Matthew Singleton | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.33 per share. | 19 Aug 2024 | 16,000 | 25,500 (0%) | 0% | 3.3 | 53,280 | Common Stock, par value $0.00001 per share |
| Viking Therapeutics Inc | J. Matthew Singleton | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Aug 2024 | 16,000 | 0 | - | - | Stock Option (Right to Buy) | |
| Viking Therapeutics Inc | J. Matthew Singleton | Director | Sale of securities on an exchange or to another person at price $ 61.86 per share. | 19 Aug 2024 | 4,509 | 15,444 (0%) | 0% | 61.9 | 278,931 | Common Stock, par value $0.00001 per share |
| Viking Therapeutics Inc | J. Matthew Singleton | Director | Sale of securities on an exchange or to another person at price $ 61.13 per share. | 19 Aug 2024 | 3,047 | 19,953 (0%) | 0% | 61.1 | 186,248 | Common Stock, par value $0.00001 per share |
| Viking Therapeutics Inc | J. Matthew Singleton | Director | Sale of securities on an exchange or to another person at price $ 60.01 per share. | 19 Aug 2024 | 2,500 | 23,000 (0%) | 0% | 60.0 | 150,035 | Common Stock, par value $0.00001 per share |
| Viking Therapeutics Inc | J. Matthew Singleton | Director | Sale of securities on an exchange or to another person at price $ 64.10 per share. | 19 Aug 2024 | 2,388 | 11,001 (0%) | 0% | 64.1 | 153,080 | Common Stock, par value $0.00001 per share |
| Viking Therapeutics Inc | J. Matthew Singleton | Director | Sale of securities on an exchange or to another person at price $ 63.15 per share. | 19 Aug 2024 | 2,055 | 13,389 (0%) | 0% | 63.2 | 129,775 | Common Stock, par value $0.00001 per share |
| Viking Therapeutics Inc | J. Matthew Singleton | Director | Sale of securities on an exchange or to another person at price $ 64.88 per share. | 19 Aug 2024 | 1,501 | 9,500 (0%) | 0% | 64.9 | 97,385 | Common Stock, par value $0.00001 per share |
| Viking Therapeutics Inc | J. Matthew Singleton | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Aug 2024 | 20,786 | 0 | - | - | Stock Option (Right to Buy) | |
| Viking Therapeutics Inc | J. Matthew Singleton | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.00 per share. | 14 Aug 2024 | 20,786 | 30,286 (0%) | 0% | 8 | 166,288 | Common Stock, par value $0.00001 per share |
| Viking Therapeutics Inc | J. Matthew Singleton | Director | Sale of securities on an exchange or to another person at price $ 57.52 per share. | 14 Aug 2024 | 20,626 | 9,660 (0%) | 0% | 57.5 | 1,186,397 | Common Stock, par value $0.00001 per share |
| Viking Therapeutics Inc | J. Matthew Singleton | Director | Sale of securities on an exchange or to another person at price $ 58.37 per share. | 14 Aug 2024 | 160 | 9,500 (0%) | 0% | 58.4 | 9,339 | Common Stock, par value $0.00001 per share |
| Viking Therapeutics Inc | Singleton Matthew J. | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2024 | 32,000 | 32,000 | - | - | Stock Option (Right to Buy) | |
| Viking Therapeutics Inc | J. Matthew Singleton | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2023 | 22,000 | 22,000 | - | - | Stock Option (Right to Buy) | |
| Viking Therapeutics Inc | J. Matthew Singleton | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2022 | 22,000 | 22,000 | - | - | Stock Option (Right to Buy) | |
| Viking Therapeutics Inc | J. Matthew Singleton | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jan 2021 | 22,000 | 22,000 | - | - | Stock Option (Right to Buy) |